Previous research suggests that α‐MG promotes fibroblast‐like synoviocyte death in RA via the ROS/ERK1/2 pathway, reversing RA development in a dose‐dependent manner (Sheng et al. 2019). This evidence concerns the gene MAPK3 and rheumatoid arthritis.